Lanreotide autogel
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
May 24, 2021 → Jan 13, 2023
NCT ID
NCT04852679About Lanreotide autogel
Lanreotide autogel is a phase 3 stage product being developed by Ipsen for Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04852679. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04852679 | Phase 3 | Completed |
| NCT02275338 | Phase 2 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutathera® | Novartis | Pre-clinical | 23 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 33 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 49 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 38 |